VVOS (Vivos Therapeutics) ROCE %: -373.15% (As of Mar. 2026)

What is Vivos Therapeutics ROCE %?

Vivos Therapeutics VVOS +9.34% 41 ROCE % is -373.15% as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vivos Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -373.15%.

Vivos Therapeutics (NAS:VVOS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vivos Therapeutics ROCE % Related Terms

Vivos Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Vivos Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics ROCE % Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-92.86

-151.30

-334.29

-162.52

-228.90

Vivos Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-185.61	-148.62	-100.15	-201.94	-373.15

41GF Score

Vivos Therapeutics Inc VVOS

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vivos Therapeutics ROCE % Calculation

Vivos Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-19.894	/	( ( (15.284 - 4.978)	+	(25.152 - 18.076) )	/ 2 )
	=	-19.894	/	( (10.306	+	7.076)	/ 2 )
	=	-19.894	/	8.691
	=	-228.90 %

Vivos Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-26.46	/	( ( (25.152 - 18.076)	+	(25.043 - 17.937) )	/ 2 )
	=	-26.46	/	( ( 7.076	+	7.106 )	/ 2 )
	=	-26.46	/	7.091
	=	-373.15 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -373.15% mean?

Vivos Therapeutics (VVOS) has a ROCE % of -373.15% as of Mar. 2026.

Is Vivos Therapeutics' ROCE % too high?

Vivos Therapeutics' current ROCE % is -373.15%. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Vivos Therapeutics' ROCE % compare to XAIR and TNON?

Vivos Therapeutics' ROCE % of -373.15% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current ROCE % is -373.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vivos Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.49 — trading 57.5% below its estimated fair value. The current ROCE % is -373.15%. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current ROCE % is -373.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivos Therapeutics (VVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued. The current stock price of $0.49 is trading 57.5% below its estimated GF Value™ of $1.16. GuruFocus considers Vivos Therapeutics to be Possible Value Trap.

Key valuation signals for VVOS:

ROCE %: -373.15%
GF Value™: $1.16 vs. price of $0.49 (57.5% below fair value)
GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivos Therapeutics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XAIR TNON BMRA INBS ITOC WOK TRIB AIDX NVNO STME ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

41GF Score

Get the complete analysis for VVOS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.49

Price

$1.16

GF Value

View VVOS Analysis

See ROCE % data for all stocks →